Neuromyelitis optica spectrum disorder (NMOSD) is a potentially life-threatening neuroinflammatory disease targeting the optic nerve, spinal cord, and brain.^[@R1][@R2][@R4]^ Relapses result in cumulative neurologic disabilities, are unpredictable, and are interspersed with remissions. Increased diagnostic accuracy and increased health care provider awareness have resulted in increased prevalence up to 10/100,000 in some geographic regions.^[@R5][@R6][@R8]^ This estimate equates to \>15,000 US patients and \>100,000 cases worldwide. NMOSD disproportionately affects females (up to 7:1).^[@R9],[@R10]^ Positive anti--aquaporin-4 (AQP4) antibody neuromyelitis optica (NMO-IgG) is the most common disease serotype; however, titers fail to predict disease course.^[@R11],[@R12]^ Recent evidence^[@R13],[@R14]^ suggests that cases positive for anti--myelin oligodendrocyte glycoprotein (MOG) antibody (MOG-IgG) are pathogenically distinct from NMOSD.

Although studies suggest therapeutic benefit, no treatment of NMOSD has been found to be safe and effective in prospective, adequately powered clinical trials. However, recent results from phase IIb and phase III trials are encouraging.^[@R15][@R16][@R17]^ In these trials, biologic therapeutics being evaluated include those targeting the complement C5 protein, the intereukin-6 receptor, and CD-19 protein on B cells. In addition, new and important scientific insights have recently shed light on key mechanisms underpinning NMOSD pathogenesis that may represent targets for next-generation therapeutics.^[@R18][@R19][@R21]^

By comparison, few studies have systematically examined the impact of NMOSD on quality of life (QoL) in well-characterized cohorts.^[@R22][@R23][@R25]^ Therefore, The Guthy-Jackson Charitable Foundation, Alexion Pharmaceuticals, Chugai Pharmaceutical Co., MedImmune/Viela Bio, and Ipsos Public Affairs conducted a cooperative study of NMOSD patient experience and QoL. Through an interactive survey format, patient-reported clinical, demographic, and experiential data were systematically collected from geographically dispersed patients with NMOSD across North America. The current analyses yielded novel insights that may afford potentially modifiable aspects of personal or clinical care to improve QoL in patients with NMOSD.

Methods {#s1}
=======

Clinical research standards {#s1-1}
---------------------------

### Human subjects protection {#s1-1-1}

The study was conducted in accordance with 45 Code of Federal Regulations Part 46 and the US Department of Health and Human Services policies regarding conductance of Human Subject Research. Protocols, survey instruments (figure e-1, [links.lww.com/NXI/A120](http://links.lww.com/NXI/A120)), and informed consent documents were approved by a central institutional review board. Written and verbal consent/assent were obtained before enrollment.

### Special population compliance {#s1-1-2}

The online survey instrument was compliant with the Americans with Disabilities Act. Participants were given the option of completing the survey with assistance of a relative, friend, or caregiver if physical impairments precluded independent participation.

Study goals and design {#s1-2}
----------------------

### Study goals {#s1-2-1}

Goals were (1) to gain understanding of the natural history of NMOSD from a patient-reported perspective and (2) to assess NMOSD patient QoL using a rigorous survey methodology comprising standardized and NMOSD-specific QoL measures. Both goals were intended to identify how NMOSD affects patients and in so doing identify those aspects that might be modified.

### Study design {#s1-2-2}

This study used a cross-sectional survey design. Comparative disease data were derived from published studies, which used identical standardized measures and for which parallel demographic and QoL data sets were available.

Survey themes {#s1-3}
-------------

The survey instrument assessed multiple disease impacts using quantitative Likert scales with dynamic ranges respective of each theme:

### Health-related QoL {#s1-3-1}

Three validated scales were used to assess the impact of NMOSD on health-related QoL: (1) select items from the Role-Physical and Role-Emotional subscales of the Short Form-36 (SF-36) measured the impact of NMOSD on physical and emotional health.^[@R26]^ Scores on the SF-36 subscales ranged from 0 to 100 (100 = highest functioning and 0 the lowest). The scale is normalized to average US individuals having a score of 50; (2) the MS QoL scale^[@R27]^ measured effects of pain, bowel and bladder, and sexual function; (3) the Impact of Visual Impairment Scale assessed of visual impairment affected perceived QoL.^[@R28]^

### Perceived impact of NMOSD on daily living {#s1-3-2}

Parameters were measured by (1) overall QoL (distinct from health-related QoL); (2) perceived impact on career; (3) social life; (4) personal relationships; (5) reproduction choices; (6) NMOSD-related pregnancy complications; and (7) degree to which living situation was determined by necessity.

### Diagnostic experience {#s1-3-3}

Measures included date of initial diagnosis (month/year); presenting symptoms; and diagnostic history, including time between first symptoms, initial diagnosis, and NMOSD diagnosis.

### Treatment experience {#s1-3-4}

The following data were collected: treatment history; reason for treatment change; date of most recent treatment change; perceived effectiveness of current NMOSD treatment; concerns regarding current treatment; and outlook on future treatment.

### Relapse experience {#s1-3-5}

Relapses in the previous year were measured using several aspects of impact and severity, including total number and frequency of clinically-confirmed relapses; number requiring inpatient hospitalization; treatment regimens received for relapses; average duration of relapses; and frequency of emergency/urgent care for NMOSD.

### Health care experience {#s1-3-6}

Evolution of patient interactions with health care professionals was assessed by first presentation to a health care provider with symptoms consistent with NMOSD; initial referral to an NMOSD specialist; specialty of physician diagnosing NMOSD; factors influencing choice of current physician; frequency of scheduled clinical evaluations; and level of satisfaction with NMOSD physician/health care provider.

### Economic burden {#s1-3-7}

Specific financial impact of NMOSD was estimated via time spent traveling to/from medical appointments; method of transportation; need for in-home professional care; total costs and annual out-of-pocket expenses for care; financial support received; burden of monthly out-of-pocket expenses; and perceived sufficiency of health care insurance.

### Future uncertainty {#s1-3-8}

Future concerns of worsening of disease and unpredictable development of improved therapies were assessed.

Survey translation {#s1-4}
------------------

Translation of the survey into Spanish involved a 2-step process. First, a native-speaking translation linguist reviewed documents against the source English file for consistency, terminology, and syntax. Next, a computer-aided translation tool (Translation Workspace XLiff Editor, v.2.49.1)^[@R29]^ was applied to review the instrument in contextual modules, resolving semantic ambiguity.

Eligibility and enrollment {#s1-5}
--------------------------

### Eligibility {#s1-5-1}

Participants were recruited from an opt-in digital mailing list of 2,000 individuals in the NMO advocacy community who requested information. Those fulfilling inclusion criteria were study eligible: self-reported, established diagnosis of NMO or NMOSD^[@R30],[@R31]^ and the ability to read textual content or hear questions audibly and respond to questions.

### Enrollment and implementation {#s1-5-2}

Eligible subjects were consented and enrolled. The survey instrument was implemented either by telephone or via an online interface. Both modalities offered assistance through a clinical study coordinator and provided options allowing completion in 1 session or to complete over multiple sessions. Patient-reported clinical data assessed are summarized in figure e-1 ([links.lww.com/NXI/A120](http://links.lww.com/NXI/A120)). Survey completion most commonly occurred in the patient or caregiver residence. Caregivers sometimes assisted the patient and investigator in use of the computer interface or in patient historical recall.

Informatics and data security {#s1-6}
-----------------------------

Study data were collected using a web-accessible electronic data capture system with access limited to qualified study personnel. Each patient data set was curated for quality, internal consistency, and completeness.

Statistical analyses {#s1-7}
--------------------

Descriptive statistics (medians or interquartile ranges for numeric variables; counts or percentages for categorical variables) were evaluated to assess cohort demographic diversity. Pairwise analysis of variance (ANOVA), χ^2^ tests, and Pearson or Spearman correlation analyses were used to assess magnitude and orientation of relationships between or among study variables. All analyses were performed in SPSS v. 25.0.^[@R32]^ Probability values (*p*) \<0.05 and correlation values (*r*) \> or \< 0.5 were considered significant.

Data availability {#s1-8}
-----------------

Deidentified data obtained using the survey instrument used in the current study (figure-e1, [links.lww.com/NXI/A120](http://links.lww.com/NXI/A120)) will be made available to qualified research personnel in accordance with institutional review board policies and upon request approximately 6 months following the final publication date.

Results {#s2}
=======

Cohort demographics {#s2-1}
-------------------

### Sex, race, and ethnicity {#s2-1-1}

The study population was predominantly female (N = 171; 88.6%) and comprised diverse racial/ethnic backgrounds: 71.5% Caucasian/white; 16.1% African American/black; 6.7% Asian (AS); 6.7% Hispanic/Latina/o or Spanish American; 0.5% Native American, 1.0% Pacific Islander; and 2.6% Other. The distribution exceeds 100% because individuals could select multiple categories. The sample was predominantly English speaking; 2 participants requested the Spanish survey. Race and ethnicity distribution was generally representative of the U.S. population, but reflected a smaller proportion of HL participants than expected.

### Education {#s2-1-2}

Twenty-eight percent reported completing a primary or high school education or general educational development ([figure 1A](#F1){ref-type="fig"}). Twenty-one percent hold an associates or technical degree, 30.6% hold a bachelor\'s degree, and 18.1% have a postgraduate education or professional degree. Typical of online survey research, the sample skewed slightly to a greater proportion of subjects having a higher level of education than the general US population.

![(A) Demographic patterns among the present study cohort\
(B) Relationship between physical and emotional health functioning in NMO/SD. Criteria were based on SF-36 role-physical and role-emotional health measures. The relative size of the circle represents the number of respondents with a given score. Most respondents fell within one of 3 categories, as labeled. Note that the upper left category represents a particularly resilient group of patients with very poor physical health but very robust emotional health.](NEURIMMINFL2018019588f1){#F1}

### Employment status {#s2-1-3}

Approximately 35% of the study cohort (N = 67) reported current employment ([figure 1A](#F1){ref-type="fig"}), ranging from full-time (≥40 h/wk; 21.2%) to part-time work. Nine unemployed respondents (4.6%) reported that they are actively seeking employment. Of those unemployed, 18 are full-time homemakers or caregivers, 22 are retired, and 1 is a student. Most unemployed respondents (63.7%; N = 79) reported being disabled.

### Income {#s2-1-4}

Household annual income varied widely among the study subjects ([figure 1A](#F1){ref-type="fig"}). The study population comprised a smaller proportion of participants who earned less than \$10,000 per year compared with the broader US demographic.

### Residential status and children {#s2-1-5}

Study participants resided in one of 43 US states and the District of Columbia, whereas 11 participants resided in Canada. The modal state of residence was California (N = 27; 14.8%). The majority of participants (70.5%) lived with their spouse/partner; 38.3% with their children; 10.4% were living alone at the time of study. None reported living with domestic assistance or in an institutional domicile/care facility. Most participants (73.1%) had children.

### Survey assistance and future research {#s2-1-6}

Nineteen participants (\<10%) received assistance in survey completion. One participant participated by telephone. Over 92% of study subjects (N = 179) would consider participating in a future study, whereas 8 (4.1%) declined considering a future survey and 6 (3.1%) declined to answer this question.

Overall QoL {#s2-2}
-----------

### Physical and emotional health {#s2-2-1}

Role-physical scores were relatively low but exhibited wide variability (median = 27.1 ± 36.1). Role-emotional functioning was near-average, with broad variance (median = 54.0 ± 44.9). Data exhibited bimodal distribution, with participants chiefly reporting either low or high functioning ([figure 1B](#F1){ref-type="fig"}). Although physical and emotional health were positively correlated (*r* = 0.513; *p* \< 0.05), the data also highlighted a complex health continuum ([figure 1B](#F1){ref-type="fig"}).

### Comparative QoL {#s2-2-2}

To contextualize NMOSD QoL, SF-26 data were compared with data examining other autoimmune/inflammatory disorders ([table 1](#T1){ref-type="table"}). Where results are summarized physically, NMOSD impact on QoL was rated similarly to systemic lupus erythematosus. Emotional impact of NMOSD was rated as equivalent to MS, systemic lupus erythematosus, and antiphospholipid syndrome.

###### 

Comparative impact and determinants of NMO/SD impact on QoL

![](NEURIMMINFL2018019588t1)

NMOSD-specific experience {#s3-3}
-------------------------

### Impact of disease on QoL {#s2-3-1}

Specific impacts of NMOSD on QoL are summarized in [table 1](#T1){ref-type="table"}. On average, NMOSD imposed a significant negative effect (mean = 4.58 ± 1.41; scale 1--6 \[1 = least impact, 6 = greatest impact\]); \>70% reported QoL to be greatly affected. Determinants most associated with negative QoL were pain, impact on career, and ability to work. Other factors were pain impairing day-to-day tasks, impact on social activities, bowel/bladder dysfunction, and satisfaction with sexual function. Of interest, diagnosis of NMOSD failed to strongly influence the decision to have children.

### Initial presenting Symptom(s) {#s2-3-2}

The most common initial presenting symptoms ([table 2](#T2){ref-type="table"}) were numbness and/or tingling (68.4%), difficulty walking (54.4%), and visual disturbances (52.8%). Other presenting symptoms are as in figure-e1 ([links.lww.com/NXI/A120](http://links.lww.com/NXI/A120)).

###### 

Symptoms and diagnoses of initial disease episode among patients with NMO/SD
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### Accuracy of initial diagnosis {#s3-3-3}

Nearly two-thirds of the cohort (N = 125; 64.8%) reported an initial diagnosis other than NMOSD. The most frequent were MS (N = 80; 41.4%) or nonspecific optic neuritis (N = 44; 22.7%) ([table 2](#T2){ref-type="table"}).

### Demographics and serologic status {#s2-3-4}

Participants ranged in age from 19 to 76 years (mean = 49.2 ± 12.8 years), whereas 13--73 years (mean = 44.7 ± 12.5 years) at diagnosis and 3 months to 22 years (mean = 5.0 ± 3.8 years) from diagnosis to study enrollment. Eighty-two percent carry the diagnosis of NMO (N = 158), whereas 18.1% (N = 35) were diagnosed with NMOSD. Among the entire study cohort, 118 (61.1%) reported being anti--aquaporin 4 antibody (NMO-IgG) seropositive, 41 (21.2%) NMO-IgG seronegative, and 34 (17.6%) did not know.

### Diagnostic or treatment delays {#s2-3-5}

Time from initial symptoms to correct diagnosis ranged from 0 (i.e., immediate NMO diagnosis) to 40 years (mean = 3.3 ± 6.3 years). The time from correct diagnosis to treatment initiation ranged from 0 to 11 years (mean = 6 months ± 1.7 years). The median timespan between first symptom and correct diagnosis was 6 months, and the median interval to specific treatment initiation was 3 weeks.

### Perceived efficacy of current treatment {#s2-3-6}

The mean rating of perceived effectiveness of current treatment across all participants was 8.2 ± 2.3 on the following scale (1--10): 10 = treatment works very well; 1 = treatment does not work well or at all. The most common medications were rituximab (60.6%), prednisone/corticosteroids (20.2%), and mycophenolate mofetil (17.1%). Of treatments being prescribed for at least 10% of study subjects, those receiving rituximab or mycophenolate mofetil reported highest perceived efficacy, whereas azathioprine was lowest ([table 3](#T3){ref-type="table"}). Four participants reported currently receiving no treatment, and 35 (18.1%) reported "other" treatments.

###### 

Perceived effectiveness, concerns, and history of treatment among patients with NMO/SD
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### Concerns about treatment options {#s2-3-7}

More than 50% of participants (51.8%) reported having concerns regarding their NMOSD treatment, mostly focused on future effectiveness ([table 3](#T3){ref-type="table"}). Eighty-eight participants (45.6%) reported NMO medication changes over their disease course. The majority of these patients (N = 48, 54.5%) reported changes because of poor efficacy, whereas 32 (36.4%) reported intolerable side effects. Three patients (3.4%) changed medication during pregnancy, 4 (4.5%) participated in a clinical trial, and 10 (11.4%) changed therapy because of cost ([table 3](#T3){ref-type="table"}).

### Impact of relapses {#s2-3-8}

[Table 4](#T4){ref-type="table"} summarizes relapse frequency among study participants. Fifty-two patients (26.9%) reported no relapses. Among the remaining 141 patients, 115 (81.5%) reported relapses requiring hospitalization, whereas 26 (18.5%) had relapses managed as outpatients. Forty-five participants (23.3%) reported 6 or more relapses, with 2 patients having ≥6 in the previous year. One-hundred twenty-one patients had not visited an emergency department because of relapse in the past year, whereas 6 others visited an emergency department ≥6 times. Relapses were reported as lasting \<4 weeks by 95 participants (49.2%) ([table 4](#T4){ref-type="table"}); 8 patients (4.1%) reported relapses lasting \>6 months. Most participants who experienced relapses in the past year were treated with either IV or (44%) or oral steroids (44%).

###### 

Total and annual relapse profile of study participants
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### Health care experience {#s2-3-9}

The distribution of health care professionals initially sought by patients for care is summarized in [table 5](#T5){ref-type="table"}. Primary care physicians (N = 48; 24.9%) and general neurologists (N = 47; 24.5) were most commonly consulted initially, followed by emergency department physicians (N = 41; 21.2%). The most common initial referral was to a general neurologist (N = 77; 39.8%). Fifty-two patients (26.9%) were referred to NMOSD specialist neurologists, 40 (20.7%) to an ophthalmologist, and 26 (13.4%) to a gastroenterologist. General neurologists were the most common specialists prescribing medications (∼90.6%).

###### 

Health care professionals encountered and annual expenses due to NMO/SD
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Nearly one-half of the study cohort (N = 82; 42.4%) were examined by their doctor every 6 months, most commonly coincident with rituximab infusion. Thirty-three percent (N = 64) of patients saw their doctor at 3-month intervals; 16 (8.3%) once per year, 2.6% (N = 5) every month, and 6 (3.1%) only at the time of relapse. The remainder report seeing their doctor "as needed" (N = 4) or not at all (N = 1).

Economic burden of disease {#s2-4}
--------------------------

### Costs attributable to disease {#s2-4-1}

Study participants rated monthly out-of-pocket expenses due to NMOSD as 5.71 ± 3.12 on a 10-point scale ranging from no burden (1) to significant burden (10). As summarized in [table 5](#T5){ref-type="table"}, prescription medicines accounted for the greatest portion of NMOSD medical costs for most patients (N = 88; 45.6%); many specified rituximab infusions as the single largest cost. The sole factor predictive of financial burden was receiving plasma exchange therapy during relapse. Twenty-five (13%) reported travel costs to/from health care providers as accounting for the greatest cost, whereas 18 (9%) stated hospitalization accounted for greatest cost. Eleven percent (N = 21) reported that an in-home professional caregiver provides service. Other significant costs reported were herbal supplements, psychologist visits, or medical costs not covered by Medicare.

### Total costs {#s2-4-2}

Beyond subjective financial burden of disease, the total annual expenses reported by the cohort as a whole was \$1,109,357 or an average of \$5,748 per respondent ([table 5](#T5){ref-type="table"}). The most frequently reported cost was prescription medication, with 140 participants (73.5%) reporting an average out-of-pocket cost of \$1,876 annually. Unprompted (not an original category of out-of-pocket costs), 3 participants reported lost income at an average of \$65,000 annually. Although not a categorical option, 23 respondents reported paying for specialists (including psychologists) out-of-pocket, at an average of \$1,554 annually. A large number of participants (N = 124; 64.2%) reported travel costs to medical appointments, at an average of \$468 per respondent. The largest total cost out-of-pocket was for hospitalization, accounting for \$304,410 annually in the sample, or an average of \$7,248 per respondent (N = 42; 21.8%). Caregiver or support was another high cost, accounting for \$70,580 annually in the sample, or an average of \$3,361 per respondent (N = 21; 10.9%).

### Financial support for care {#s2-4-3}

The majority of study participants (N = 142; 73.6%) reported that health insurance sufficiently covered prescribed NMOSD medicines. Among those with insufficient health insurance, expensive copayment and insurer denials were common reasons. Twenty-four study participants (12.6%) reported receiving financial support for their NMOSD treatment, largely in the form of disability insurance, clinical trial participation, or support from friends and family.

Correlation analysis {#s2-5}
--------------------

To examine predictors of overall QoL, ANOVA was used to detect correlates among individual factors, including time since diagnosis, total relapse number (a surrogate of disease severity), and current treatments (overall and specifically for relapses). Neither time since diagnosis nor current treatment regimen was predictive of overall QoL; however, the number of relapses correlated significantly with overall QoL (*p* = 0.001), with greater numbers of relapses diminishing QoL.

Other potential correlates affecting QoL in NMOSD were explored using a matrix Pearson or Spearman correlation analysis of primary data elements. As shown in [table 6](#T6){ref-type="table"}, multiple correlations were identified as trending to positively or negatively affecting QoL.

###### 

Exploratory correlation analyses among study data elements†
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Discussion {#s3}
==========

The primary goal of this study was to determine the impact and correlates of NMO on patient QoL in a standardized manner using validated measures of physical and emotional health impact on daily activities potentially affecting QoL. By examining specific tangible domains of QoL in parallel to perceived overall QoL, the patient experience regarding how this rare disease affects daily life was revealed.

Several important themes were identified among the current study cohort. First, NMOSD typically has strong negative effects on physical functioning. Physical functioning was lower in the study cohort than in the general population and on par with individuals having MS or systemic lupus erythematosus.^[@R33][@R34][@R36]^ The predominant physical issues affecting QoL were bodily pain, bowel and bladder dysfunction, and visual impairment. These factors inversely correlated with ability to work, the limitation of which negatively affected QoL. Age was positively associated with many QoL measures such as pain, suggesting that disease increasingly negatively affctes QoL over time. Worse physical functioning also correlated with greater uncertainty about the future. Notably, anti-AQP4 antibody serostatus reported as negative or unknown correlated with less impact on QoL than detectable anti-AQP4 antibody. This relationship is similar to that often observed in AQP4 antibody--positive and MOG antibody--positive phenotypes.^[@R11][@R12][@R14]^ Conversely, seronegative status carried a significantly higher financial burden.

By comparison, emotional health was in general unimpaired, suggesting that poor physical health does not necessarily correspond to diminished emotional health. Although some study participants exhibited congruent emotional and physical health, a subset of participants reported the highest level of emotional health despite seriously impaired physical health. This inverse relationship suggests a degree of psychological resilience in some patients despite physical impairment. Likewise, a portion of participants reported that their disease had a positive effect on their social relationships. One possible explanation for such positive impact is that their disease provoked support network involvement. These findings are consistent with the concept and impact of psychological resilience,^[@R38]^ which can translate to effective personal strategies of coping with health-related challenges.^[@R39]^

The constellation of presenting symptoms in many patients resulted in an initial diagnosis of MS. Inaccurate diagnosis combined with delay of appropriate therapy can negatively affect long-term outcomes in NMOSD.^[@R40]^ However, recent implementation of international consensus criteria^[@R31]^ has increased the timeliness and accuracy of diagnosis and should improve care in early disease.^[@R41]^ The number, duration, and severity of relapses varied widely across the study cohort. This observation corresponds to the absence of a standardized definition and diagnostic algorithm for differentiating bona fide relapses from unrelated symptoms.

Not surprisingly, participants reporting higher treatment ratings also experienced higher physical and emotional functioning and higher QoL. Similarly, worse functioning was associated with larger financial burden. These themes are concordant with those of previous studies.^[@R22],[@R23],[@R41]^ Of interest, patients receiving nonspecific immune-suppressing treatments tended to rate their regimens more negatively, whereas those on target-specific treatments (e.g., biologics) rated their treatments more positively. Impact of NMO on QoL extended beyond physical and emotional costs; respondents reported a high financial burden, particularly for prescription medicines, travel costs, hospitalization, and specialist care. Furthermore, the per-respondent cost and total cost estimates in this study provide a useful estimate of personal and health care costs of NMOSD to society.

Results of the current study emphasize the significant negative impact NMOSD can have on patient QoL, particularly in relation to physical disability, pain, bowel and bladder dysfunction, or visual impairment.^[@R42][@R43][@R46]^ These manifestations correspond to reduced ability to work at a job or perform daily activities, and a decreased QoL, which also reconcile with negative impacts of anxiety, disability, or depression in NMOSD.^[@R25],[@R47]^ Factors contributing to these adverse outcomes may include (1) delayed or inappropriate treatment due to initial misdiagnosis; (2) real or perceived efficacy or lack of efficacy of current treatment options; (3) lack of a standard definition of relapse; and (4) disease-specific economic burden. These issues underscore the importance of recent advances in diagnostic timeliness and accuracy, as well as ongoing clinical trials intended to establish the first approved therapies for NMOSD. Prospectively, global collaboration aimed at implementation of a standard relapse definition and severity score should contribute to improved clinical care. Likewise, the pursuit of predictive biomarkers of relapse to allow mitigating interventions and the initiation of studies aimed to durably restore immune tolerance as a curative therapy hold promise for increasingly effective medical solutions for NMOSD patients. Synergistic and prospective approaches such as these aimed at addressing disease causes and effects hold great promise to significantly add to the QoL for patients with NMOSD, other patients with rare disease, and beyond.^[@R48],[@R49]^
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